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with Cerebellar Ataxia and Seizures
Julie Mollet,1 Agne`s Delahodde,2 Vale´rie Serre,1 Dominique Chretien,1 Dimitri Schlemmer,1
Anne Lombes,3 Nathalie Boddaert,4 Isabelle Desguerre,5 Pascale de Lonlay,5 He´le`ne Ogier de Baulny,6
Arnold Munnich,1 and Agne`s Ro¨tig1,*
Coenzyme Q10 (CoQ10) plays a pivotal role in oxidative phosphorylation (OXPHOS) in that it distributes electrons between the various
dehydrogenases and the cytochrome segments of the respiratory chain. Primary coenzyme Q10 deﬁciency represents a clinically hetero-
geneous condition suggestive of genetic heterogeneity, and several disease genes have been previously identiﬁed. The CABC1 gene, also
called COQ8 or ADCK3, is the human homolog of the yeast ABC1/COQ8 gene, one of the numerous genes involved in the ubiquinone
biosynthesis pathway. The exact function of the Abc1/Coq8 protein is as yet unknown, but this protein is classiﬁed as a putative protein
kinase. We report here CABC1 gene mutations in four ubiquinone-deﬁcient patients in three distinct families. These patients presented
a similar progressive neurological disorder with cerebellar atrophy and seizures. In all cases, enzymological studies pointed to ubiqui-
none deﬁciency. CoQ10 deﬁciency was conﬁrmed by decreased content of ubiquinone in muscle. Various missense mutations
(R213W, G272V, G272D, and E551K) modifying highly conserved amino acids of the protein and a 1 bp frameshift insertion
c.[1812_1813insG] were identiﬁed. The missense mutations were introduced into the yeast ABC1/COQ8 gene and expressed in a Saccha-
romyces cerevisiae strain in which the ABC1/COQ8 gene was deleted. All the missense mutations resulted in a respiratory phenotype with
no or decreased growth on glycerol medium and a severe reduction in ubiquinone synthesis, demonstrating that these mutations alter
the protein function.Introduction
Coenzyme Q10 (CoQ10, ubiquinone), a lipophilic compo-
nent located in the inner mitochondrial membrane, plays
a pivotal role in oxidative phosphorylation (OXPHOS).
CoQ10 shuttles electrons from complexes I and II to com-
plex III. CoQ10 also plays a critical function in antioxidant
defenses. CoQ10 deﬁciency [MIM607426] represents a clin-
ically heterogeneous and largely under-diagnosed condi-
tion. This clinical heterogeneity is suggestive of a genetic
heterogeneity, and several disease genes have been hith-
erto identiﬁed. The human PDSS1 (MIM 607429) and
PDSS2 (MIM 610564) genes encode the two subunits of
the prenyl diphosphate synthase (encoded by the COQ1
gene in yeast), the enzyme elongating the prenyl side
chain of ubiquinone. PDSS1-2mutations have been identi-
ﬁed in patients presenting with either multi-organ involve-
ment1 or Leigh syndrome and nephropathy.2 Similarly, the
COQ2 (MIM 609825) gene encodes the para-hydroxyben-
zoate-polyprenyltransferase that condensates the 4-OH
benzoate ring with the prenyl side chain. COQ2mutations
have been reported in a family with encephalomyopathy
and nephropathy3,4 and in a family with fatal infantile
multi-organ disease.1 Yet, because of the small size of the
families, the disease causing gene remains unknown in
most cases of CoQ10 deﬁciency.On the other hand, the quinone biosynthesis pathway
has been extensively studied in bacteria and in the yeast
Saccharomyces cerevisiae. So far, ten genes encoding pro-
teins involved in ubiquinone synthesis have been identi-
ﬁed in yeast (COQ1–COQ10). All of them except COQ1
and COQ2 catalyze hydroxylation, O-methylation, decar-
boxylation, and C-methylation reactions and contribute
to the synthesis of the fully substituted ubiquinone.5 On
the basis of protein homology, homolog genes have been
identiﬁed in humans. Despite their unknown exact func-
tion, they represent obvious candidate genes for quinone
deﬁciency in humans.
The CABC1 (MIM 606980) gene is the human homolog
of the yeast ABC1/COQ8 gene. ABC1 (for Activity of bc1
complex) has been initially identiﬁed as a multicopy sup-
pressor of a cytochrome b translation defect, and the
Abc1p was believed to act as a chaperon-like protein of
the bc1 complex.6 More recently, ABC1 has been shown
to complement the coq8-1 mutant defective in ubiqui-
none synthesis.7 ABC1 and COQ8 therefore represent one
single gene. The exact function of the Abc1/Coq8 protein
is as yet unknown, but this protein is classiﬁed as a putative
protein kinase based on the presence of kinase motifs in its
amino acid sequence. The yeast ABC1/COQ8 gene is the
homolog of the ubiB and aarF genes required for the ﬁrst
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Figure 1. Brain MRI of Patients 1 and 2
The sagittal T1 showed an important cerebellar atrophy in both patients. The axial T2 also revealed abnormal hyperintensities in the
posterior cerebral regions. The diffusion-weighted imaging (DWI) showed a normal apparent diffusion coefficient in these posterior
regions. These abnormalities were interpreted as a stroke-like episode.prokaryotes E. coli and P. stuartii, respectively.8,9 CABC1
(Chaperone activity of bc1 complex), the human counter-
part of the yeast ABC1/COQ8 gene, is also called COQ8 or
ADCK3.
We report here onCABC1 genemutations in four ubiqui-
none-deﬁcient patients belonging to three distinct fami-
lies. These patients were considered to be respiratory-chain
deﬁcient because they presented with a progressive neuro-
logical disorder with cerebellar atrophy, developmental
delay, and hyperlactatemia. Reduced amounts of ubiqui-
none in their muscle prompted us to systematically study
the human genes involved in ubiquinone synthesis and
to eventually identify various missense or frameshift
CABC1 mutations in these children.
Material and Methods
Patients
Patient 1 is the second child of healthy, unrelated parents originat-
ing from the Reunion Island. An older sister is healthy. Patient 1
was able to walk unaided at 1 year, but he fell frequently. This
was at ﬁrst ascribed to proximal muscle weakness at 18 months.
Cerebellar ataxia and strabismus were diagnosed 6 months later.
At 2.5 years of age, he presented generalized tonic seizures with
high CSF lactate (4 mmol/liter, n < 2 mmol/liter). He was given
rivotril and valproate (675 mg/kg/day) orally, and these controlled
seizures for the following ﬁve years. At 3 years of age, he still pre-
sented trunk hypotonia and a slight intellectual regression. He624 The American Journal of Human Genetics 82, 623–630, Marchreceived oral CoQ10 (5 mg/kg/day) from age 3 years, 8 months
to age 4, and then he was put on higher doses (10 mg/kg/day)
from age 4 to age 7, with no clinical beneﬁts. Because of his unre-
sponsiveness to oral CoQ10, he was put on a short-chain quinone,
idebenone (10 mg/kg/day), which not only failed to improve his
condition but also worsened the course of the disease and was
therefore discontinued after 7 months. His neurological condition
worsened at 12 years of age, and 1 year later he was unable to
walk or speak, and the number of seizures increased. Brain MRI
performed at 12 years of age revealed severe cerebellar atrophy
and stroke-like anomalies with hyperintensity on T2 and FLAIR
(Figure 1). At 16 years, he has epilepsia partialis continua and consis-
tently elevated plasma lactate (3 mmol/liter, n ¼ 1.0–1.55 mmol/
liter) as well as an elevated L/P ratio (18, n ¼ 6–14). A histological
study of his skeletal muscle at 6 years revealed mitochondrial
accumulation and lipid droplets in 10%–20% of the ﬁbers. No
ragged-red ﬁbers were observed.
Patient 2 is the third child of healthy, unrelated parents of
French origin. Two older siblings are healthy (Figure 2). Patient 2
was normal at birth but presented mild hypotonia in the ﬁrst
months of life. She could sit unaided at 9 months and walk at 2
years but presented talus valgus. Developmental delay was ﬁrst
noted at 18 months. At 8 years, she presented seizures controlled
by oral sodium valproate. Then she developed cerebellar ataxia
and ptosis with brain MRI evidence of vermis hypoplasia. At 14
years of age, she had epilepsia partialis continua. She has been on
oral CoQ10 (20 mg/kg/day) since then with no clinical beneﬁt.
Brain MRI at that age revealed a severe cerebellar atrophy with
stroke-like anomalies and hyperintensities on T2 and FLAIR
(Figure 1).2008
Patient 3 is the younger sister of patient 2. Her clinical course is
similar to that of her sister. She is now 13 years old and presents
a cerebellar ataxia.
Patient 4 has been previously reported.10 An early intolerance to
exercise was followed by progressive cerebellar syndrome and
cerebellar atrophy.
All procedures were approved by the review board of the Necker
Hospital. We obtained informed consent from parents of all
patients and siblings before collecting blood for DNA extraction
or performing tissue biopsies.
Enzyme Studies and Analysis of CoQ10 Content
Polarographic tests and/or spectrophotometric respiratory-chain
enzyme assays were carried out on skeletal-muscle mitochondria,
muscle homogenate, or cultured skin ﬁbroblasts as previously de-
scribed.11 Quinones from frozen muscle (3–10 mg), cultured skin
ﬁbroblasts, and yeast were extracted and quantiﬁed as previously
described.1 All solvents (Merck) were HPLC grade. The various
yeast strains were grown in 5 ml of glucose minimum medium
for 60 hr and then in YPGal for 12 hr. Total yeast extracts were ob-
tained after spheroblasting the cells according to Mamnun et al.,12
Quinones were extracted and quantiﬁed as previously described.1
Quinone content in yeast was expressed as the ratio CoQ6/CoQ10,
where CoQ10 (10 mM) was used as an internal standard.
Mutation Screening
The exons and exon-intron boundaries of the human CABC1 gene
were PCR ampliﬁed with speciﬁc intronic primers (Table 1). Am-
pliﬁcation products were directly sequenced with the PRISM
Ready Reaction Sequencing Kit (Perkin-Elmer) on an automatic
sequencer (Applied Biosystems).
Complementation of a Yeast coq8 Null Mutant
The R77W, G130V, G130D, and E409K mutations, corresponding
to the human R213W, G272V, G272D, and E551K mutations, re-
spectively, were introduced into the wild-type yeast COQ8 gene
cloned in pFL44 (gift from G. Dujardin) with the site-speciﬁc mu-
tagenesis kit (Stratagene) and speciﬁc primers (Table 1; mutations
are shown in brackets). The yeast Dcoq8 strain (gift from G. Dujar-
din; ade2, leu2, trp1, his3, ura3, coq8::LEU2) was transformed
according to Gietz et al.,13 and the resulting clones were grown
on WO plates supplemented with appropriate amino acids and
replicated on a glycerol-rich medium for 3–4 days at 30C.
Results
Enzymologic Studies and Quinone Quantiﬁcation
A severe impairment ofmalateþpyruvate and succinate ox-
idation was observed in muscle mitochondria of patient 1
(Table 2). Assessment of individual OXPHOS enzyme activ-
ities in this tissue revealed normal CIV activity but severely
reduced CIIþIII activity. Respiratory-chain enzyme activi-
ties in his cultured skin ﬁbroblasts were normal, but a slight
increase in the CIV/CIIþIII ratio was observed. In patient 2,
muscle mitochondria displayed high individual enzyme
activities, but CIV/CIIþIII and CIIþIII/CII activity ratios
were also elevated, indicating quinone deﬁciency. Simi-
larly, high respiratory-chain activities and a slight increase
of CIV/CIIþIII were noted in her cultured skin ﬁbroblast.
Enzyme activities in muscle mitochondria were substan-
tially increased by the addition of decylubiquinone (DQ,
an exogenous ubiquinone analog, Table 2), again suggest-
ing quinone deﬁciency. Addition of DQ resulted in a 40%
induction of CIIþIII activity (276 and 396 nmol/min/mg
protein before and after DQ addition, respectively).
Figure 2. Pedigree and Haplotype Analysis in a Multiplex
Family: Patients 2 and 3
Haplotypes are given (top to bottom) for loci D1S439, D1S479,
CDC42BPA, D1S2805, and D1S225.
Table 1. Primers
































Mutations are shown in parentheses.
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Table 2. Respiratory-Chain Enzyme Activities in Muscle Mitochondria and Cultured Skin Fibroblasts
Muscle Mitochondria Muscle Mitochondria Muscle Homogenate Fibroblasts
P1 Control P2 Control P4a Ca P1 P2 Control
Activities (nmol/min/mg protein)
malateþglutamate oxidase <8* 805 30 - - - -
malateþpyruvate oxidase <8* 805 30 - - - -
succinate oxidase <8* 915 26 85 59.55 12.2 - - -
glycerol-3-P oxidase - 19.9 11.95 2.3 - - -
CI - 143 735 15 76 225 7 60 88 41 5 5
CII - 162 985 20 71 315 8 98 139 74 5 8
CIII - 2030 14585 257 337 1075 26 1052 1197 7625 103
CIV 2334 31515 760 1281 7405 146 99 565 17 538 798 3845 44
CV - 372 3355 68 - 140 132 1105 14
CIþIII - - 4* 175 10
CIIþIII 48* 7285 122 276 2335 48 6* 185 7 155 279 1385 16
CIIþIII activation by DQ - - 43%* 0% - 0% 0%
CS 2415 26245 694 - 956 1535 35 255 247 238.55 25.6
Activity Ratios
CIV/CS 1.8 1.35 0.3 - - 2.1 3.2* 1.7 5 0.2
CIIþIII/CS 0.016* 0.335 0.08 - - 0.6 1.13* 0.58 5 0.1
CIV/CIIþIII 48* 45 1.3 4.6* 3.25 0.3 - 3.4* 2.9* 2.0 5 0.2
CIIþIII/CII - 1.7* 2.55 0.2 - - 2.0 2.1 5 0.2
Enzyme activities on muscle mitochondria have been determined in two different laboratories for patients 1 and 2. Abnormal values are indicated with an
asterisk.
a Previously published by Aure et al., 2004.10Direct evidence of quinone deﬁciency was eventually
provided by quantiﬁcation of CoQ10 in the patients’ mus-
cle. Indeed, the muscle CoQ10 content was markedly
decreased in patient 1 and in the lower control values in
patient 2 (Table 3). The quinone content was normal in
cultured skin ﬁbroblasts from patients 1 and 4.
Molecular Studies
The genes known to be involved in ubiquinone biosynthe-
sis were systematically studied by direct sequencing in pa-
tients 1–4. Patient 1 carried a homozygous G-to-A transi-
tion at nucleotide 1655 in exon 14 of the CABC1 gene.
This transition resulted in the change of a highly con-
served glutamic acid into a lysine (E551K, Figure 3). Both
parents were heterozygous for this mutation. Patients 2
and 3 showed haploidentity for markers D1S439,
D1S479, D1S2805, and D1S225 surrounding CABC1
Table 3. Quinone Content in Muscle and Cultured Skin
Fibroblasts
P1 P2 Control P4a Controla
Muscle
(pmol/mg muscle)
2.6* 9.4* 32.2 5 9.8
(n ¼ 42)
<1 mg/g* 19–30 mg/g
Fibroblasts
(pmol/mg protein)
125 - 1205 32
(n ¼ 13)
normal
Quinone content was determined in two different laboratories as pmol/mg
muscle for patients 1 and 2 and as mg/g for patient 4. Abnormal values are
indicated with an asterisk.
a Previously published by Aure et al., 2004.10626 The American Journal of Human Genetics 82, 623–630, March 2gene, as well as for the intragenic CDC42BPA marker,
whereas their healthy siblings presented distinct haplo-
types (Figure 2). They were compound heterozygotes for
a C-to-T transition inherited from the father at nucleotide
636 (R213W) and a G-to-T transversion inherited from the
mother at nucleotide 815 (G272V, Figure 3). Both muta-
tions resulted in the modiﬁcation of highly conserved res-
idues in the protein. The two healthy siblings were hetero-
zygous carriers for the R213W mutation. Finally, patient 4
was a compound heterozygote for one missense G-to-A
transition inherited from the father at nucleotide 815
(G272D) and one base pair insertion inherited from the
mother c.[1812_1813insG] (Figure 3). When RT-PCR am-
pliﬁcation of ﬁbroblast RNAs was performed with primers
in the last exon, it showed that the abnormal transcript
was still present in patient 4 (not shown). This ﬁnding sug-
gests that a resulting mutant protein might be synthesized
in this patient (728 instead of 647 amino acids). None of
the c.[1655G > A] or c.[815G > A] mutations were found
in more than 460 chromosomes. However, heterozygosity
for the c.[636C > T] and c.[815G > T] mutations were
found in 2/440 (0.45%) and 3/470 (0.64%) controls,
respectively.
Functional-Complementation Studies
To conﬁrm the deleterious nature of the various CABC1
mutations, we tested mutant genes for their ability to com-
plement the respiratory-chain defect in the Saccharomyces
cerevisiae strain deleted for the ABC1/COQ8 gene. We in-
troduced the various missense mutations into the yeast008
ABC1/COQ8 gene cloned in the pFL44 high-copy plasmid
by site-directed mutagenesis. We used the wild-type and
the four different mutant plasmids to transform a yeast
Dabc1/coq8 null strain. Growth of the mutant on glyc-
erol-rich medium was restored by the wild-type yeast
ABC1/COQ8 gene (Figure 4A). However, the yeast G130D
Figure 3. Sequence analysis of the CABC1 gene in patients 1–4 (upper panel) and sequence alignment of the CABC1 proteins
from human and non-human sources (lower panel). The arrows indicate the various mutations
Figure 4. Functional Analysis of CABC1 Mutations
(A) Functional complementation of the yeast abc1/coq8 null mutant. Growth of abc1/coq8 null mutant on either glucose (WO-HAT
20 g/liter glucose) or glycerol medium was compared (YPGly, 20 g/liter glycerol). The yeast Dabc1/coq8 null mutant was transformed
with the wild-type (wt), R77W, G130V, G130D, and E409K mutant ABC1/COQ8 yeast genes cloned in pFL44 plasmid. The four spots for
each experiment correspond to decreasing dilutions of transformed yeasts.
(B) Quinone content in transformed Dabc1/coq8 null mutants. CoQ6 content was measured by mass spectrometry and expressed as CoQ6/
CoQ10. CoQ10 was used as an internal standard.
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protein corresponding to the human G272D protein com-
pletely failed to complement the yeast mutant (Figure 4A).
The yeast E409K and G130V proteins corresponding to the
human E551K and G272V proteins presented a very weak
growth on glycerol medium (Figure 4A). Finally, the R77W
mutation corresponding to the human R213W mutation
resulted in slightly decreased growth on glycerol medium
(Figure 4A). Because yeast synthesizes CoQ6 as ubiquinone,
we then measured the CoQ6 amount in the various trans-
formed Dcoq8 null strains and observed a severe reduction
of ubiquinone in these mutant strains. A more severe re-
duction was observed for the G130D (0% of wild-type ubi-
quinone content), whereas the R77W mutation displayed
only 12% of control ubiquinone values (Figure 4B). These
results demonstrate that the various tested mutations
altered the protein function.
Discussion
This study ﬁrst reports the identiﬁcation of deleterious
CABC1 mutations in three unrelated families of various
origins. These mutations were identiﬁed in children with
respiratory-chain deﬁciency and reduced ubiquinone in
muscle tissue. The clinical presentation of the patients
was relatively similar. Indeed, the patients presented with
muscle weakness and abnormal exercise fatigability be-
tween 18 months and 3 years. Then, they all developed
cerebellar ataxia and MRI evidence of severe cerebellar
atrophy. Seizures were characteristic of epilepsia partialis
continua. Finally, no CABC1 mutations could be identiﬁed
in a series of seven patients with ubiquinone deﬁciency
and various clinical presentations such as cardiomyopathy,
Leigh syndrome, and multisystemic involvement. Several
disease gene mutations have been hitherto reported in
patients with ubiquinone deﬁciency and various clinical
presentations. The small number of families unfortunately
hampers genotype-phenotype correlation. Our present
results suggest that CABC1mutations form a homogenous
group of ubiquinone deﬁciency. Finally, secondary ubiqui-
none deﬁciency in patients with myopathy due to ETFDH
mutations has been described and seems to represent a
clinically and genetically homogenous entity.14
Despite clinical homogeneity, patients carrying CABC1
mutations displayed various degrees of respiratory-chain
impairment and ubiquinone deﬁciency. Indeed, patients
1 and 4 showed severely decreased muscle ubiquinone
content, resulting in low CIIþIII and/or CIþIII activities,
whereas ubiquinone content in the muscle of patient 2
was in the lower control values. In this last case, only stim-
ulation of CIIþIII activity by DQ suggested a ubiquinone
deﬁciency. Interestingly, patient 2 carried the less severe
mutations (R213W and G272V), as shown when these
were expressed in the Dcoq8 null yeast strain. One can
hypothesize that CABC1 mutations cause a more severe
ubiquinone defect in CNS than in muscle, although mus-
cle is the only available tissue. For this reason, we suggest
systematically looking at DQ stimulation when perform-628 The American Journal of Human Genetics 82, 623–630, Marching CIIþIII assays. It should bementioned that normal ubi-
quinone amounts were detected in ﬁbroblasts of patients 1
and 4 and revealed a tissue-speciﬁc ubiquinone deﬁciency.
The various CABC1 mutations reported here affect
highly conserved amino acids of the protein. The exact
function of the CABC1 protein in humans and other or-
ganisms is still unknown. It has been suggested that
Abc1 in yeast could act as a putative protein kinase, but
none of the mutations identiﬁed here lie in any kinase do-
main. All the missense mutations, when introduced in the
yeast ABC1/COQ8 gene, resulted in a respiratory pheno-
type with no or decreased growth on glycerol medium
and a severe reduction in ubiquinone synthesis. We ob-
served a clear correlation between the growth defect on
glycerol and the residual CoQ6 content; the lower CoQ6
content was observed for the more severe growth defects.
Interestingly, the R77W yeast protein resulted in a mild
growth defect, whereas the CoQ6 content was signiﬁcantly
reduced. It appears therefore that a low residual CoQ6 con-
tent allows a signiﬁcant growth on selective medium.
Finally, the frameshift mutation found in patient 4 is
supposed to modify a highly conserved domain of the
protein. It has been shown in yeast that ABC1/COQ8 can
suppress coq9 mutants, suggesting that the two genes
and proteins are functionally related.15 Stable physical in-
teraction between the two proteins could not be observed
in yeast; nevertheless, transient interaction cannot be
excluded. One can hypothesize that the abnormal C-ter-
minal end of the mutant protein resulting from the
c.[1812_1813insG] insertion could alter a putative interac-
tion or regulation between the Coq8 and Coq9 proteins.
On the basis of evidence of ubiquinone deﬁciency, the
patients were given oral ubiquinone supplementation.
This resulted in a slight improvement of patient 4, but
a progressive cerebellar ataxia appeared 2 years later. Pa-
tients 1–3 did not signiﬁcantly improve upon ubiquinone
administration. Yet, the parents observed a slight improve-
ment after one year. Activation of CIIþIII activity in mus-
cle mitochondria and the rescue of yeast Dabc1/coq8 mu-
tant growth by Q6 supplementation
7 suggest that the
respiratory-chain deﬁciency caused by CABC1 mutations
in humans (or in the yeast abc1/coq8 null mutant) is
rapidly corrected by exogenous quinone. Therefore, the
absence of spectacular improvement after oral quinone
supplementation suggests an insufﬁcient uptake of
CoQ10 across the blood-brain barrier in our patients.
Genes involved in ubiquinone biosynthesis in humans,
including CABC1, are ubiquitously expressed. Why muta-
tions in this gene as well as in other ubiquinone-synthesis
genes resulted in different clinical presentations and tis-
sue-speciﬁc ubiquinone deﬁciency is intriguing. One can
hypothesize that different organs have different ubiqui-
none requirements. According to another hypothesis, the
expression level of the various proteins involved in ubiqui-
none synthesis could be different in various tissues. It has
been shown in yeast that coq3–coq9 mutants accumulate
the same intermediate hexaprenylhydroxybenzoate162008
and that Coq3, Coq4, Coq6, and Coq7 proteins form
a complex.17 Coq8 protein does not seem to be involved
in this complex but should be coordinately regulated
with the proteins of this complex. Considering the high
homology between yeast and human proteins involved
in ubiquinone synthesis, it is tempting to speculate that
such a complex also exists in humans. This would ob-
viously require a coordinated and possibly tissue-speciﬁc
regulation of the corresponding genes. Therefore, dysfunc-
tion in any of these proteins could result in changes in
the other protein levels, perhaps with a tissue-speciﬁc
response.
CABC1 is a target of the p53 tumor suppressor gene and
is therefore the third p53-regulated gene in mitochondrial
disorders.18 Indeed, SCO2 mutations resulted in cardioen-
cephalomyopathy and cytochrome oxidase deﬁciency,19
and it has been recently shown that aerobic respiration is
regulated by p53 via SCO2 expression.20 Finally, we re-
cently identiﬁed p53R2, encoding the p53-controled small
ribonucleotide reductase, as a new gene of mitochondrial
DNA depletion.21 None of the patients with CABC1,
SCO2, or p53R2 mutations show major evidence of in-
creased apoptosis or tumor susceptibility, suggesting that
p53 not only is involved in the suppression of tumor devel-
opment but could also play an as-yet-unknown function
(including mitochondrial control) during cell life.
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